# FIDES-01 (NCT03230318)

> Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

No report yet. It can be ordered.

- Drugs tested: derazantinib
- Indication: FGFR2 fusion-, mutation- or amplification-positive advanced intrahepatic cholangiocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03230318
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Basilea Pharmaceutica
- Conditions: Intrahepatic Cholangiocarcinoma; Combined Hepatocellular and Cholangiocarcinoma
- Interventions: derazantinib
- Enrollment: 148
- Primary outcome: Substudy 1: Objective Response Rate (ORR)
- Primary outcome: Substudy 2: Progression Free Survival at 3 Months (PFS 3)

## Indexed commentary on FIDES-01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=fides-01-nct03230318